DISEASE CHARACTERISTICS:

• Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer

• Recurrent disease after platinum-based chemotherapy

  • Must have experienced disease persistence during primary platinum-based therapy or recurrence within 12 months after completion of platinum-based chemotherapy ("platinum-refractory" or "platinum-resistant" disease)

    • A patient receiving a second course of platinum-based chemotherapy for platinum-sensitive disease who then develops persistence or recurrence within 12 months is considered eligible for this trial
• Must have measurable disease by RECIST criteria (phase II)

• Must have received ≥ 1 prior platinum-based cytotoxic chemotherapy regimen (for primary disease) containing carboplatin, cisplatin, or other organoplatinum compound

  • Initial treatment may have included any of the following:

    • High-dose therapy
    • Consolidation therapy
    • Intraperitoneal (IP) therapy
    • Extended therapy administered after surgical or nonsurgical assessment
  • One additional non-cytotoxic regimen (e.g., monoclonal antibodies, cytokines, or small-molecule inhibitors) for recurrent or persistent disease allowed
• Patients may have received hormonal therapy for management of disease (e.g., SERMs, aromatase inhibitors, progestins, and GnRH agonists)
• No loculated ascites for which IP distribution of virus is not expected to be feasible
• No known brain metastases

PATIENT CHARACTERISTICS:

Inclusion criteria:

• GOG performance status (PS) 0-2 (Karnofsky PS 60-100%)
• Life expectancy > 12 weeks
• Leukocytes ≥ 3,000/mcL
• Absolute neutrophil count ≥ 1,500/mcL
• Hemoglobin ≥ 10 g/dL
• Platelets ≥ 100,000/mcL
• Total bilirubin normal
• AST/ALT ≤ 2.5 times upper limit of normal
• Creatinine normal
• Ejection fraction > 50% by echocardiogram or MUGA
• Cardiac enzymes normal
• Not pregnant or nursing
• Fertile patients must use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation
• Must be able to avoid direct contact with pregnant or nursing women, infants, or immunocompromised individuals while on study and for ≥ 3 weeks following the last dose of study agent administration
• Cardiac conduction abnormalities (e.g., bundle branch block, heart block) are allowed if their cardiac status has been stable for 6 months before study entry

Exclusion criteria:

• Patients in whom insertion of an IP catheter is not feasible due to surgical contraindications or abdominal and pelvic adhesions
• Known HIV infection or hepatitis B or C

• Clinically significant cardiac disease (New York Heart Association class III or IV cardiac disease) including any of the following:

  • Pre-existing arrhythmia
  • Uncontrolled angina pectoris
  • Myocardial infarction 1 year prior to study entry
  • Compromised left ventricular ejection fraction ≥ grade 2 by MUGA or echocardiogram
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

• See Disease Characteristics
• At least 4 weeks since most recent cytotoxic chemotherapy (6 weeks for nitrosoureas or mitomycin C)
• Recovered from adverse events due to agents administered more than 4 weeks earlier
• No prior radiotherapy to the abdomen or pelvis
• No other concurrent investigational agents
• No investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's malignancy

Exclusion criteria:

• Chronic oral steroids at an equivalent dose of prednisone 5 mg daily

  • Inhaled steroids allowed
• Patients on immunosuppressive therapy
• Concurrent routine prophylactic use of growth factor (filgrastim [G-CSF] or sargramostim [GM-CSF])